Skip to main content
. 2024 Apr 16;39(2):206–221. doi: 10.3803/EnM.2024.1940

Fig. 3.

Fig. 3.

Comparison of bodyweight (A) and abdominal visceral fat (B) from baseline to week 68 for semaglutide 2.4 mg, semaglutide 1.7 mg, and placebo in Janpanese and Korean people with obesity. Adapted from Kadowaki et al. [49], with permission from Elsevier. VFA, visceral fat area.